See All
Preferences
My Communities
My Discussions
My Email Digests


It is because of her desire to bring liver disease research to the forefront that she was asked to serve on the AASLD's Development Committee. Dr. Palmer began asking her patients enrolled in clinical trials to donate their stipends to The Liver Research Fund to support AASLD's research awards, educational grants, and programs. She asked AASLD to create information that could be distributed to her patients once she realized that many of her patients were willing to donate, but that they needed information on where and how to do so.
AASLD created a flyer stand, flyers, and postage-paid reply envelopes for display in offices, and these items have made it easier for Dr. Palmer's patients to donate to The Liver Research Fund.
Since Dr. Palmer started asking her patients for donations, they have given more than $9000 to The Liver Research Fund. "I hope this will spur enthusiasm among my peers to help raise funds for AASLD. Promoting The Liver Research Fund through my office is a component of my personal commitment to quality liver care," she enthuses.
Members of AASLD can request the fundraising stand, flyers, and information by contacting Heidi Bruce, Director of Development, by email to hbruce@aasld.org or by phone at (703) 299-9766.
Please click here to read the entire interview with Dr. Palmer.
This electronic newsletter is a bi-weekly publication of AASLD and replaces the former bi-monthly print newsletter and weekly e-news. Members are welcome to submit articles and may send suggestions to aharan@aasld.org .View Thread


Please call 516 939 2626 for details.View Thread

Aim: To determine if simplifying the dosing regimen of RBV impacts outcomes.
Methods: Ninety-two patients on RBP >12 weeks were categorized as follows: Group A
(n = 22): treatment experienced with IFN/PIFN and RBV, Group B (n = 49): treatment
naïve switched to RBP after >12 weeks RBV, Group C (n = 21): treatment naïve on
RBP. Outcomes were compared between RBP and RBV in Groups A and B. Group C
was compared to Group D—a matched control group of RBV-treated patients.
Results: Patients preferred RBP. RBP was associated with improved patient compliance,
less side effects, improved quality of life and a trend toward improved SVR.
Conclusions: RibaPak offers an attractive alternative to RBV.RibaPak blister packs offer an attractive alternative to traditional RBV bottled pills.
Patients prefer RibaPak compared to RBV due to
decreased number of pills, convenience of the blister
pack administration, diminished side effects (primarily
GI) and improved quality of life. RibaPak is associated with
improved patient compliance compared to RBV. This
has the potential to avoid wasted drug costs and reduce
future comorbidity that is associated with significant
health care expense. As the future of HCV treatment
will likely involve the addition of a third drug (such as
a polymerase or protease inhibitor), simplification of
the treatment regimen by a reduction in the number of
pills may be crucial to treatment success.View Thread

Among the 96 treatment-naive patients, the SVR rate was 79% in the triple therapy arm, compared with 61% in the nitazoxanide-pegylated interferon dual therapy arm, and 50% in the standard-of-care arm (P = 0.023).
• Among the 24 treatment-experienced patients, the SVR rate was 25% in the triple therapy arm compared with 8% in the nitazoxanide-pegylated interferon arm.
• RVR, EVR, and ETR rates are shown in the table below (see next study description).
• Adverse events were generally similar across all 3 treatment arms.
• The exception was that the rate of anemia was significantly lower in the group that did not receive ribavirin.View Thread

Table. Factors Affecting SVR Rates

Women's Health Newsletter
Find out what women really need.
Other Hepatitis Information
More Related Communities
The opinions expressed in WebMD User-generated content areas like communities, reviews, ratings, or blogs are solely those of the User, who may or may not have medical or scientific training. These opinions do not represent the opinions of WebMD. User-generated content areas are not reviewed by a WebMD physician or any member of the WebMD editorial staff for accuracy, balance, objectivity, or any other reason except for compliance with our Terms and Conditions. Some of these opinions may contain information about treatments or uses of drug products that have not been approved by the U.S. Food and Drug Administration. WebMD does not endorse any specific product, service, or treatment.
Do not consider WebMD User-generated content as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource, but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.
Health Solutions From Our Sponsors
©2005-2013 WebMD, LLC. All rights reserved.
WebMD does not provide medical advice, diagnosis or treatment. See additional information.



